{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ortiz JR"],"funding":["NCATS NIH HHS","NIAID NIH HHS"],"pagination":["3253-3262"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9897630"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(23)"],"pubmed_abstract":["<h4>Background</h4>Influenza A/H7N9 viruses have pandemic potential.<h4>Methods</h4>We conducted an open-label, randomized, controlled trial of AS03-adjuvanted 2017 inactivated influenza A/H7N9 vaccine (H7N9 IIV) in healthy adults. Group 1 received H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later. Group 2 received IIV4 alone and then two doses of H7N9 IIV at three-week intervals. Group 3 received one dose of IIV4. We used hemagglutination inhibition (HAI) and microneutralization (MN) assays to measure geometric mean titers and seroprotection (≥1:40 titer) to vaccine strains and monitored for safety.<h4>Results</h4>Among 149 subjects, seroprotection by HAI three weeks after H7N9 IIV dose 2 was 51% (95 %CI 37%-65%) for Group 1"],"journal":["Vaccine"],"pubmed_title":["Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial."],"pmcid":["PMC9897630"],"funding_grant_id":["UM1 AI148372","HHSN272201300023I","UL1 TR003098","HHSN272201200003I","75N93021C00012","HHSN272201300016C","HHSN272201300023C","HHSN272201300016I","R01 AI145332","HHSN272200800057C"],"pubmed_authors":["Neuzil KM","Ortiz JR","Overton ET","Wegel A","Goepfert PA","Cross K","Chen WH","Buddy Creech C","Logan HL","Parker S","Spearman PW","Dickey M"],"additional_accession":[]},"is_claimable":false,"name":"Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.","description":"<h4>Background</h4>Influenza A/H7N9 viruses have pandemic potential.<h4>Methods</h4>We conducted an open-label, randomized, controlled trial of AS03-adjuvanted 2017 inactivated influenza A/H7N9 vaccine (H7N9 IIV) in healthy adults. Group 1 received H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later. Group 2 received IIV4 alone and then two doses of H7N9 IIV at three-week intervals. Group 3 received one dose of IIV4. We used hemagglutination inhibition (HAI) and microneutralization (MN) assays to measure geometric mean titers and seroprotection (≥1:40 titer) to vaccine strains and monitored for safety.<h4>Results</h4>Among 149 subjects, seroprotection by HAI three weeks after H7N9 IIV dose 2 was 51% (95 %CI 37%-65%) for Group 1","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-28T19:00:44.545Z","creation":"2025-02-19T00:13:26.072Z"},"accession":"S-EPMC9897630","cross_references":{"pubmed":["35465983"],"doi":["10.1016/j.vaccine.2022.03.055"]}}